Consumer Medicine Information
What is in this leaflet
This leaflet is designed to provide you with answers to some common questions about
this medicine. It does not contain all the available information and does not take
the place of talking with your doctor.
All medicines have risks and benefits. Your doctor has more information about this
medicine than is contained in this leaflet. Also, your doctor has had the benefit
of taking a full and detailed history from you and is in the best position to make
an expert judgement to meet your individual needs.
If you have any concerns about taking this medicine, talk to your doctor or pharmacist.
Keep this leaflet with this medicine.
You may need to read it again.
What EVIFYNE is used for
EVIFYNE belongs to a group of non-hormonal medicines called Selective Estrogen Receptor
Modulators (SERMs). When a woman reaches menopause, the level of the female sex hormone,
oestrogen, goes down. EVIFYNE mimics some of the beneficial effects of oestrogen after
EVIFYNE is used to prevent and treat osteoporosis in women after menopause.
Osteoporosis causes your bones to become thin and fragile - it is especially common
in women after menopause. While osteoporosis may have no symptoms at first, it makes
your bones more likely to break, especially in your spine, hips and wrists. Osteoporosis
may also cause back pain, loss of height and a curved back.
Fractures may occur during normal, everyday activity, such as lifting, or from minor
injury that would not ordinarily fracture normal bone.
EVIFYNE is also used to reduce the risk of invasive breast cancer in women with osteoporosis
after menopause and reduce the risk of invasive breast cancer in women at high risk
of invasive breast cancer after menopause.
Breast cancer is invasive when it has spread outside the milk duct or milk-making
glands and has grown into normal tissue inside the breast. Invasive cancers can spread
cancer to other parts of the body through the bloodstream and lymphatic system.
Your doctor may have prescribed EVIFYNE for another reason.
Ask your doctor if you have any questions about why EVIFYNE has been prescribed for
This medicine is available only with a doctor's prescription.
Before you take EVIFYNE
Tell your doctor if you have any of the following conditions or if you have ever experienced
any of these conditions.
When you must not take EVIFYNE
Do not take EVIFYNE:
if you have not been through menopause. EVIFYNE is only for use by women after menopause
and must not be taken by women who could still have a baby.
if you have had an allergic reaction to EVIFYNE or any of the ingredients listed at
the end of this leaflet (see 'Product Description'). Signs of an allergic reaction
may include a skin rash, itching, shortness of breath or swelling of the face, lips
if you are being treated or have been treated for blood clots.
if the packaging is torn or shows signs of tampering, or if the tablets do not look
if the expiry date on the pack has passed. If you take this medicine after the expiry
date has passed, it may not work as well.
If you are not sure whether you should start taking EVIFYNE, talk to your doctor or
Before you start taking EVIFYNE
You must tell your doctor:
if you have any unexplained vaginal bleeding.
if you are at risk of blood clots.
if you are, or know you will be immobilised for some time, e.g., being wheel-chair
bound or having to stay in bed while recovering from an operation or illness.
if you have liver disease.
if you are intolerant of lactose. EVIFYNE contains a small amount of lactose (about
150 mg) which is unlikely to affect you.
if you have menopausal symptoms, such as hot flushes. EVIFYNE does not treat hot
if you are breastfeeding.
if you are on oestrogen or hormone replacement therapy (HRT).
if you have or have had high blood fats (triglycerides) caused by oestrogen.
if you have previously had a stroke, or if you have ever had other risk factors for
stroke such as a mini-stroke (transient ischaemic attack) or a type of irregular heartbeat
called atrial fibrillation
if you have had breast cancer. EVIFYNE has not been fully studied in women who have
a history of breast cancer.
Before starting and while taking EVIFYNE you should have breast examinations and mammograms,
as directed by your Doctor. EVIFYNE does not eliminate the chance of developing breast
cancers, you need these examinations to find any breast cancers as early as possible.
EVIFYNE is not intended to be taken by men.
EVIFYNE has no known effect on driving or the ability to use machinery.
Taking other medicines
Tell your doctor if you are taking any other medicines, including any that you buy
without a prescription from your pharmacy, supermarket or health food shop.
Some medicines and EVIFYNE may interfere with each other. These include:
medicines for your heart such as digitalis drugs (e.g. digoxin) or blood thinning
drugs such as warfarin. Your doctor may need to adjust the dose of these medicines.
hormone replacement therapy (HRT) or oestrogens.
lipid-lowering drugs including cholestyramine.
Your doctor or pharmacist has more information on medicines to be careful with or
avoid while taking EVIFYNE.
Tell your doctor about these things before taking EVIFYNE.
How to take EVIFYNE
Carefully follow all directions given to you by your doctor or pharmacist.
These may differ from the information contained in this leaflet.
How much to take
The usual dose of EVIFYNE is one tablet per day.
How to take it
EVIFYNE tablets should be swallowed whole with a glass of water.
When prescribed for the treatment or prevention of osteoporosis, EVIFYNE should be
taken in conjunction with supplementary calcium if daily calcium intake is inadequate.
When to take it
It does not matter what time of day you take your tablet. However, it is best to
take it at the same time each day as this will help you remember to take it.
The days of the week are printed on the blister foil to help you take your tablet
You may take EVIFYNE with or without food.
How long do I take it
For maximum benefit, EVIFYNE is intended for long-term use.
Do not stop taking EVIFYNE without first talking to your doctor.
If you forget to take it
If it is almost time for your next dose, skip the tablet you missed and take your
next dose when you are meant to.
Otherwise, take it as soon as you remember then go back to taking your medicine as
you would normally.
Do not take a double dose to make up for the dose that you missed.
If you are not sure what to do, ask your doctor or pharmacist.
If you take too much
Immediately telephone your doctor or the Australian Poisons Information Centre (13
11 26), or the New Zealand National Poisons Information Centre (0800 POISON or 0800
764 766), or go to the Accident and Emergency Department at your nearest hospital,
if you think that you or anyone else has taken too much EVIFYNE.
Do this even if there are no signs of discomfort or poisoning.
In adults, symptoms of an overdose may include leg cramps and dizziness.
In children, symptoms of an overdose may include coordination problems, dizziness,
vomiting, rash, diarrhoea, repetitive shaking, and flushing.
While you are taking EVIFYNE
Things you must do
It is important that you remember to take EVIFYNE daily and at the dose prescribed
by your doctor.
Tell all doctors and pharmacists who are treating you that you are taking EVIFYNE.
While you are taking EVIFYNE, tell your doctor or pharmacist before you start any
If you become pregnant while taking EVIFYNE, tell your doctor.
Tell your doctor if you are immobilised for some time, e.g., being wheel-chair bound
or having to stay in bed while recovering from an operation or illness.
If you are going on a long plane or car trip, you should move about periodically.
Tell your doctor if you have any vaginal bleeding.
Things you must not do
Do not stop taking EVIFYNE without first checking with your doctor.
Do not give EVIFYNE to anyone else, your doctor has prescribed it specifically for
Tell your doctor or pharmacist as soon as possible if you experience any undesirable
effect or feel unwell while you are taking EVIFYNE.
Like other medicines, EVIFYNE may cause some unwanted side effects. These are likely
to vary from patient to patient.
The majority of side effects seen with EVIFYNE have been mild.
Tell your doctor if you notice any of the following side effects and they worry you:
swelling of hands, feet and legs
These are the more common side effects of EVIFYNE.
Tell your doctor immediately or go to the Accident and Emergency Department at your
nearest hospital if you notice any of the following:
severe pain or swelling in your legs
severe stomach pain
problems with your eyesight
shortness of breath or pain on breathing
In clinical trials of EVIFYNE, some women experienced blood clots in the veins (venous
thromboembolic events). This occurred in less than 1% of EVIFYNE patients. This
is a serious side effect. You may need urgent medical attention or hospitalisation.
Tell your doctor if you notice anything unusual or if you are concerned about any
aspect of your health, even if you think the problems are not associated with this
medicine and are not referred to in this leaflet.
Clinical trials using EVIFYNE have shown that:
Women taking EVIFYNE have less swelling, tenderness and pain in their breasts than
women receiving oestrogen.
Unlike oestrogen, EVIFYNE has no effect on the uterus and is unlikely to cause vaginal
bleeding or spotting.
After taking EVIFYNE
Keep your tablets in the blister pack until it is time to take them.
Keep your tablets in a cool, dry place where the temperature stays below 30°C.
All medicines should be kept where young children cannot reach them.
There will be an expiry date (month, year) on your EVIFYNE pack.
The medicine should not be taken after this date because it may have lost some of
If your doctor tells you to stop taking EVIFYNE or you find that the tablets have
passed their expiry date, please return any left over tablets to your pharmacist.
What it looks like
EVIFYNE tablets are white, oval shaped and film coated. Each EVIFYNE tablet has the
identicode number '4165' printed on it in blue ink.
In Australia EVIFYNE tablets come in blister packs containing 7 (sample pack) and
In New Zealand EVIFYNE tablets are available in blister packs containing 28 tablets.
Active Ingredient - raloxifene.
Each EVIFYNE tablet contains 60 mg of raloxifene hydrochloride which is equivalent
to 56 mg raloxifene.
Inactive Ingredients - lactose, lactose monohydrate, povidone, polysorbate 80, crospovidone,
magnesium stearate, Colour Mixture White YS-1-18027-A (PI 2673), carnauba wax and
trace amounts of OPACODE BLUE S-1-10537G (PI 3536) and OPACODE S-1-10537G BLUE (PI
EVIFYNE is a product of:
Eli Lilly Australia Pty Limited
112 Wharf Road
West Ryde NSW 2114
Australian Registration Number:
AUST R 172550
This leaflet was revised in December 2019.